RNAI-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONS

• Main Authors: GAMACHE, DANIEL A, CHATTERTON, JON E, YANNI, JOHN M, MILLER, STEVEN T
• Format: Patent
• Language: English; French
• Published: 03.04.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease. L'invention concerne une interférence de l'ARN assurant l'inhibition de l'expression de l'ARNm de la tyrosine kinase de rate (Syk), en particulier pour traiter des patients ayant une condition inflammatoire apparentée à Syk ou étant à risque de développer une condition inflammatoire apparentée à Syk telle que la conjonctivite allergique, l'inflammation oculaire, la dermatite, la rhinite, l'asthme, l'allergie ou une maladie des mastocytes.